TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02950974
Drug: Sterofundin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluid loading
Study: NCT00548691
Drug: Standard Medical Care (SMC)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04171310
Drug: SAR442168
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form:oral solution Route of administration: Oral
Study: NCT02058407
Drug: GSK2793660 solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clear, colourless solution at a unit dose strength of 0.1 mg/mL, in a glass bottle
Study: NCT02058407
Drug: GSK2793660 capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Size zero swedish orange capsule at a unit dose of 3 mg, 10 mg, 20 mg and 50 mg
Study: NCT02058407
Drug: Placebo solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo to GSK2793660 solution
Study: NCT02058407
Drug: Placebo capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo to GSK2793660 capsule
Study: NCT00001476
Drug: Gene Therapy Method for CGD
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01433081
Drug: Placebo infusion of .9 normal saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: administration of .9 normal saline
Study: NCT01431092
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both Circadin and placebo are encapsulated in lactose containing gelatin capsules to optimize the blinding.
Study: NCT01431092
Drug: Melatonin
Normalized name: Melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Prolonged-release melatonin (Circadin®) 2 mg, once daily, 1-2 hours before bedtime.
Study: NCT03390673
Drug: HD204
Normalized name: Hydrocodone/Acetaminophen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-Dose 1mg/kg body weight by 90 minute intravenous infusion
Study: NCT03093870
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000mg/m2, oral tablets, twice daily for 2 weeks followed by a 1-week rest period in 3-week cycles. Number of cycles: until disease progression, unacceptable toxicity, withdrawal of consent, or death.
Study: NCT03093870
Drug: Placebo (for Varlitinib)
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral tablets, twice daily. Number of cycles: until disease progression, unacceptable toxicity, withdrawal of consent, or death
Study: NCT01103518
Drug: Ethinyl Estradiol + Cyproterone acetate
Normalized name: cyproterone / ethinyl estradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethinyl Estradiol (0.035mg) + Cyproterone acetate (2mg), coated tablets. Each treatment cycle consists of one tablet, once per day for 21 days followed by a 7-day rest period. A total of 4 treatment cycles will be completed during the study treatment period.
Study: NCT01225224
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT01293955
Drug: JOINS 200mg
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet at each time, 3 times a day
Study: NCT01293955
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo of Joins 200mg
Study: NCT01531829
Drug: Low Molecular Weight Heparin
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1ml/10kg,q12h,5-7 days
Study: NCT04675619
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment
Study: NCT04281576
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine 1000mg/m\^2 taken by mouth, twice daily on day 1-14, 3 weeks per cycle
Study: NCT00004061
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01345942
Drug: RO5428029
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose
Study: NCT03303066
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT02810132
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: See above
Study: NCT01682720
Drug: SOF
Normalized name: Kasof
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sofosbuvir (SOF) 400 mg tablet administered orally once daily
Study: NCT01682720
Drug: Placebo to match SOF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match SOF administered orally once daily
Study: NCT01682720
Drug: Placebo to match RBV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match RBV administered orally in a divided daily dose
Study: NCT02654483
Drug: VPD-737
Approvals — FDA: no, EMA: no, PMDA: no
Description: VPD-737 inhibits the receptor neurokinin-1.
Study: NCT02527083
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00625729
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 60 mg/kg intravenous (IV) on Day -5.
Study: NCT01742052
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01274247
Drug: Topical Benzocaine
Normalized name: benzocaine Topical Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical administration of a drop of benzocaine to the lingual frenulum
Study: NCT01656720
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01766089
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Remifentanil (0.1 µg/kg/min) starting 5 min before induction of anaesthesia and continued until peritoneal closure.
Study: NCT01171937
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Children get randomized to either placebo or risperidone
Study: NCT01064284
Drug: PLASMA DERIVED Factor VIII
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maximum dosage : 50IU per kilo. 2-3 times per week or on demand during acute episode of bleeding
Study: NCT02677051
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03072849
Drug: FAM Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients who have evidence of early airflow obstruction on pulmonary function testing will be started on FAM therapy. Early airflow obstruction is defined by a FEV1 decline of ≥10% predicted in addition to a FVC \<0.8.
Study: NCT00694928
Drug: clindamycin phosphate/butoconazole nitrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: semi-solid, single dose
Study: NCT01670149
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets
Study: NCT00231465
Drug: ZD1839
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZD1839 will be continued until progression, or until trial closure, whichever comes first.
Study: NCT00666341
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo: Al(OH)3-Placebos with histamine-dihydrochloride analogue Allergen-Adsorbate rPhleum strengthes 1 to 4.
Study: NCT00902369
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01714388
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1mcg/kg iv dose, followed by 5 minutes ECG recording
Study: NCT01044693
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule
Study: NCT00544687
Drug: Karison® Creme
Approvals — FDA: no, EMA: no, PMDA: no
Description: topical Karison® Creme (clobetasol-17-propinate 0.05%)
Study: NCT00544687
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: topical (placebo)
Study: NCT02714543
Drug: aloevera juice
Normalized name: tamarind juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: aloevera juice to drink twice daily for 3 months.
Study: NCT02714543
Drug: Hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: intralesional injection of hydrocortisone 100mg once a week for 6 weeks
Study: NCT02714543
Drug: antioxidant
Normalized name: ANTIOXIDANT GS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules SM Fibro (antioxidants) once daily for 3 months.
Study: NCT01310114
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thawed placebo
Study: NCT01483430
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 capsule/day (starch), Duration: 8 weeks
Study: NCT00283985
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3 gr/m2 at J1
Study: NCT00088881
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00088881
Drug: doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT02596893
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04038008
Drug: Diflucan®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diflucan® is manufactured by Fareva Amboise, France (MAH: PFIZER PHARMA PFE GmbH, Germany). Each hard capsule contains 200 mg of fluconazole.
Study: NCT03106402
Drug: topical bromfenac sodium hydrate
Normalized name: Bromfenac Sodium
DrugBank: Bromfenac (DB00963)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00926900
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT04279769
Drug: CB-280
Normalized name: BroveX CB
Approvals — FDA: no, EMA: no, PMDA: no
Description: CB-280, oral capsule administered twice daily at the assigned dose level for 14 days
Study: NCT04279769
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral capsule administrated twice daily at the assigned dose level for 14 days
Study: NCT01052428
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 100 mg once a day for 2 years
Study: NCT00092742
Drug: MK0663, etoricoxib
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00092742
Drug: Comparator: Diclofenac sodium
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02729012
Drug: hypertonic saline solution (NACL 3%+NAHCO3)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with nebulized hypertonic saline solution (NACL 3%+NAHCO3)
Study: NCT02773537
Drug: Adductor canal catheter only
Normalized name: Canalevia
Approvals — FDA: no, EMA: no, PMDA: no
Description: This nerve block is believed to cause numbness only, without any muscle weakness. A catheter remains in place for up to 36 hours after surgery for the purpose of adding additional medication should the patient require it. This technique causes only the front of the knee to be numb
Study: NCT02336555
Drug: MK-8291
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-8291 oral tablets
Study: NCT02336555
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral tablets
Study: NCT01366014
Drug: ARRY-371797, p38 inhibitor; oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: multiple dose, single schedule
Study: NCT01366014
Drug: Placebo; oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo
Study: NCT04843839
Drug: Nepafenac 0.1% Oph Susp
Normalized name: NEPAFENAC 0.1% OPH SUSP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nepafenac 0.1% eye drops - Allergan : Dosage- 1 drop QID for 6 months
Study: NCT04843839
Drug: Refresh Tears 0.5% Lubricant Eye Drops
Normalized name: Refresh Tears 0.5% Lubricant Eye Drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: Refresh Tears 0.5% w/v eye drops - Allergan : Dose- 1 drop QID for 6 months
Study: NCT01749293
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subjects in this trial will receive Cyclophosphamide 50 mg/kg IV QD on Days 3 and 4 post-transplant.
Study: NCT03992482
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal Saline Eye Drops (0.9% NaCl) two times a day for eight weeks
Study: NCT03636269
Drug: CR845 0.5 mcg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV CR845 0.5 mcg/kg administered three times/week
Study: NCT03636269
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV placebo administered three times/week
Study: NCT02091830
Drug: Paracetamol and nonsteroidal antiinflammatory drug (NSAID)
Normalized name: codeine and paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02242903
Drug: LY3079514
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT02242903
Drug: LY3079514
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered IV
Study: NCT02242903
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT02242903
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered IV
Study: NCT02105012
Drug: BD MDI 160 µg
Normalized name: immunoglobulin G, human 160 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide Inhalation Aerosol administered as 2 inhalations BID
Study: NCT02105012
Drug: BD MDI 80 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide Inhalation Aerosol administered as 2 inhalations BID
Study: NCT02105012
Drug: Placebo MDI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo MDI administered as 2 inhalations BID
Study: NCT04370847
Drug: Intrathecal Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl 15 μg will be administered in the subarachnoid space
Study: NCT04370847
Drug: Intravenous Syntocinon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediately after delivery, syntocinon 10 IU will be added to the running crystalloid solution.
Study: NCT04504669
Drug: AZD8701
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOXP3 antisense oligonucleotide
Study: NCT02124421
Drug: Adjuvant Chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Six weeks post-surgery (CRS or CRS/HIPEC) standard combination chemotherapy will be administered every 21 days for 6 cycles
Study: NCT02813824
Drug: Acetylsalicylic acid lysinate 300 mg
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daily dose during 4 years
Study: NCT02813824
Drug: Placebo (for Aspirin 300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily dose during 4 years
Study: NCT02813824
Drug: Acetylsalicylic acid lysinate 100 mg
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daily dose during 4 years
Study: NCT02813824
Drug: Placebo 100 (for Aspirin 100)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily dose during 4 years
Study: NCT00128492
Drug: AZLI 75 mg two times a day (BID)/ three times a day (TID)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02728726
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered intravenously at 2 mg/kg after routine reversal of anesthesia is performed and subject is extubated.
Study: NCT02597361
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo o.d. to match 150mg or 300mg irbesartan tablets
Study: NCT02533128
Drug: Liberal blood pressure management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocolized hemodynamic management to maintain mean arterial pressure (MAP) \> 60 mmHg
Study: NCT02533128
Drug: Tight blood pressure management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocolized hemodynamic management to maintain mean arterial pressure (MAP) \> 75 mmHg
Study: NCT02002195
Drug: FOLFOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxaliplatin 85 mg/m2 is given as a 2 hours intravenous infusion, concomitant to and S-leucovorin 200 mg/m2, and followed by 5-FU 2,400 mg/m2 as a 46 hours continuous infusion.
Study: NCT02002195
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine 1,000 mg twice a day will be administered until disease progression, unacceptable toxicity or treatment refusal by the patient.
Study: NCT00216658
Drug: fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03599726
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 5 mg per day for week 1-2 or 5-6
Study: NCT04156100
Drug: AGEN1223
Approvals — FDA: no, EMA: no, PMDA: no
Description: AGEN1223 is a bispecific antibody.
Study: NCT04082325
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to Lu AF88434 oral solution, single dose
Study: NCT04018950
Drug: ETX2514
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous infusion
Study: NCT00063362
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients were assigned in a one to one ratio to adjunctive lamotrigine versus placebo after stratification for illness type (bipolar I versus bipolar II), historical response to lithium (response versus non-response), and length of current exposure to combination treatment with lithium and divalproex (\< 2 months versus ≥ 2 months). During Phase 2, patients were continued on the same doses of lithium and divalproex as during the open-label treatment phase and equal capsules of double-blind lamotrigine or matching placebo were gradually added per a structured dosing schedule up to a minimum dose of 150 mg and a maximum dose of 200 mg per day.
Study: NCT03194932
Drug: Intrathecal Triple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IT.
Study: NCT03401580
Drug: Viena II 160/10
Approvals — FDA: no, EMA: no, PMDA: no
Description: once daily
Study: NCT03401580
Drug: Viena II 190/10
Approvals — FDA: no, EMA: no, PMDA: no
Description: once daily
Study: NCT03401580
Drug: Viena II 160/12
Approvals — FDA: no, EMA: no, PMDA: no
Description: once daily
Study: NCT03401580
Drug: Viena II 190/12
Approvals — FDA: no, EMA: no, PMDA: no
Description: once daily
Study: NCT03399747
Drug: Abb-R-CHOP
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: Completely Excised LocalizedGastrointestinal CD20 (+) Diffuse Large B-cell Lymphoma~3 Cycles(1 Cycle:4weeks) of Rituximab Plus CHOP (Cyclophosphamide, Adriamycin, Vincristine, and Prednisolone) Immunochemotherapy
Study: NCT01943084
Drug: Norditropin® FlexPro® pen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as a single subcutaneous (s.c., under the skin) dose (4.0 mg) on 2 separate dosing visits (treatment periods). The 2 treatment periods will be separated by a 7-day washout period.
Study: NCT01943084
Drug: Genotropin Pen®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as a single subcutaneous dose (4.0 mg) on 2 separate dosing visits (treatment periods). The 2 treatment periods will be separated by a 7-day washout period.
Study: NCT03142334
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion
Study: NCT00920270
Drug: antibiotics
Normalized name: Antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: conventional parenteral antibiotics
Study: NCT00298545
Drug: Calcium and Calcitriol
Normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium twice daily together with an oral tablet of 1, 25 dihydroxy vitamin D3 (Calcitriol)
Study: NCT00494988
Drug: insulin NPH
Normalized name: insulin NPH human isophane
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01779206
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00113126
Drug: Treatment interruption
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03680131
Drug: EB01 Cream Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle Cream containing 0% EB w/w applied BID
Study: NCT03680131
Drug: EB01 Cream 0.2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: EB01 Cream containing 0.2% EB01 w/w applied BID
Study: NCT03680131
Drug: EB01 Cream 1.0%
Approvals — FDA: no, EMA: no, PMDA: no
Description: EB01 Cream containing 1.0% EB01 w/w applied BID
Study: NCT03680131
Drug: EB01 Cream 2.0%
Approvals — FDA: no, EMA: no, PMDA: no
Description: EB01 Cream containing 2.0% EB01 w/w applied BID
Study: NCT04331769
Drug: Guideline-Directed Medical Therapy
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guideline-Directed Medical Therapy
Study: NCT00989339
Drug: Twenty-four Hour TPN and Saline Infusion
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of Intralipid 20%, ClinOleic 20% or normal saline at 20 ml/hr for 24 hr.
Study: NCT01392976
Drug: CO-1.01 Formulation A (Aqueous suspension containing 15 mg/mL of drug solubilized in purified phospholipids)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1250 mg/m2 intravenous infusion on Day 1 for Treatment Sequence 1 and Day 8 for Treatment Sequence 2.
Study: NCT01392976
Drug: CO-1.01 Formulation B (Aqueous suspension containing 30 mg/mL of drug solubilized in purified phospholipids)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1250 mg/m2 intravenous infusion on Day 1 for Treatment Sequence 2 and Day 8 for Treatment Sequence 1.
Study: NCT01428453
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo comparator
Study: NCT00399360
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg twice daily increasing to 850 mg twice daily after 3 Months
Study: NCT03784326
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV (vein)
Study: NCT02626520
Drug: 5-fluorouracil and irinotecan
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFIRI.3 given every 14 days x 4 cycles
Study: NCT02014844
Drug: 250 mg/m2 aldoxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02014844
Drug: 350 mg/m2 aldoxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01157429
Drug: Placebo pill
Normalized name: placebo Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo pill by mouth prior to sessions 5-12 of teh 12-session CBT protocol.
Study: NCT02620865
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02620865
Drug: Leucovorin Calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02571855
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules matching the ACT-541468 formulations
Study: NCT00821821
Drug: MCI-186
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cohort 1: Edaravone: circa 1000 mg / 72-hour infusion~Cohort 2: Edaravone: circa 2000 mg / 72-hour infusion
Study: NCT00821821
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cohort1:circa 1000mg / 72-hour infusion matching placebo~Cohort2:circa 2000mg / 72-hour infusion matching placebo